EXL named Microsoft Solutions Partner for Data and AI
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a leading data and AI company, announced it has been recognized as a Microsoft Solutions Partner for Data and AI. This designation acknowledges EXL's advanced capabilities in helping clients manage data across systems and build transformative analytics and AI solutions on Microsoft platforms.
This designation highlights EXL's technology capabilities, high-level digital talent, and proven track record for enabling customer success with Microsoft products and platforms. Through close collaboration with Microsoft, EXL is uniquely positioned to deploy innovative tools and solutions for its clients.
'We're always looking for ways to better serve our clients data and AI goals,' said Baljinder Singh, executive vice president and global chief information officer at EXL. 'Receiving this Microsoft Solutions Partner designation is yet another advancement in how we're able to help deliver better customer experiences, data-driven decisions, and AI-powered operating models.'
As part of this accreditation, EXL has expanded its digital offerings in Microsoft Azure Marketplace, launching three innovative solutions that demonstrate the company's industry expertise in data and AI.
'Our collaboration with EXL is centered on helping organizations reimagine how they use data and AI to solve real-world challenges,' said Irina Ghose, managing director, Microsoft India & South Asia. 'By combining Microsoft's cloud and AI capabilities with EXL's solutions, we're enabling businesses to move faster, operate smarter, and unlock new opportunities for growth.'
'Achieving this recognition as a Microsoft Solutions Partner reinforces our commitment to driving success through strong partnerships and innovative technology,' said Singh. 'We are excited to continue elevating our transformational solutions we provide as part of the Microsoft ecosystem.'
EXL reimagines what is possible with Microsoft Azure, helping to reshape how companies can build smarter, faster, AI-driven enterprises. Learn more about our Azure Marketplace listings here.
About EXL
EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL harnesses the power of data, AI, and deep industry knowledge to transform businesses, including the world's leading corporations in industries including insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have approximately 60,000 employees spanning six continents. For more information, visit www.exlservice.com.
Cautionary Statement Regarding Forward-Looking StatementsContacts
Media
Keith Little
+1 703-598-0980
[email protected]
Investor Relations
John Kristoff
+1 212 209 4613
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
2 hours ago
- Forbes
Microsoft Confirms Windows 11 Automatic Deletions: Take Action Now To Protect Yourself
Microsoft's Windows 11 creates System Restore points, that is, snapshots of your PC's system files, settings and registry. But those points expire and are automatically deleted after 60 days, Microsoft has now confirmed. Users can protect themselves by creating regular System Restore points. 'With System Restore you can revert your PC's state to a previous point in time. By using System Restore, you can undo these changes without affecting your personal files,' Microsoft says. Windows 11 Which is great, but those restore points don't last forever, so it's important to know exactly how long they are there for. Previous documentation suggested that on Windows 10, restore points could last as long as 90 days. Windows Latest reports that 'After Windows 11's release in 2021, the retention period has been anywhere between 10 and 90 days (mostly 10 days),' it says. Ten days really isn't long, but there's good news. In a new support document relating to the June 10 update, Microsoft is a bit more specific. 'After installing the June 2025 Windows security update, Windows 11, version 24H2 will retain system restore points for up to 60 days. To apply a restore point, select Open System Restore. Restore points older than 60 days are not available. This 60-day limit will also apply to future versions of Windows 11, version 24H2,' it says. In other words, Microsoft has confirmed that Windows 11 System Restore points will be deleted after 60 days, so you need to periodically create restore points. That's not as good as 90 days, obviously, but way better than 10 days. 'This will give you multiple snapshots, but Windows will still delete the oldest ones once they exceed the retention window (now 60 days on Windows 11 24H2 by default),' says Windows Latest. To create your own System Restore point, as Windows Latest explains, you open Start and search for 'Create a restore point,' which will open System Protection tab in System Properties. Next, under Protection Settings, check that one of the partitions where you're going to put the backup is protected. Choose that partition and Configure to turn on protection. Then, click Create and follow the onscreen instructions. This will last for 60 days. Now that the deletion date is clear, it seems like creating one every few weeks is good practice.
Business Upturn
3 hours ago
- Business Upturn
OGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting Investors have until July 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Hauser v. Organon & Co., et al. , No. 25-cv-05322. Why was Organon Sued for Securities Fraud? Organon is a global healthcare company focused on women's health that has historically rewarded its shareholders with a healthy dividend. In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions. As alleged, while the acquisition increased Organon's debt, the Company assured investors it would maintain its dividend, which Organon asserted was its '#1 capital allocation priority.' In truth, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt, ultimately leading the Company to severely cut its dividend. The Stock Declines as the Truth is Revealed On May 1, 2025, Organon announced that management reset the Company's dividend payout from $0.28 per share to $0.02 per share. Organon's CEO explained that the Company 'reset our capital allocation priorities to accelerate progress towards deleveraging' and that '[b]y deleveraging more rapidly, we will continue to strengthen the future prospects of the company.' Organon's CFO added, '[t]he biggest issues we face . . . relate to managing our leverage and relate to growth. And we need capital to solve both of those issues, and so returning capital to shareholders is right now, less of a priority.' On this news, the price of Organon stock declined roughly 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025. Click here if you suffered losses: What Can You Do? If you invested in Organon you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
3 hours ago
- Business Upturn
IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al. , No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
